QGE031 + Placebo
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedAbout QGE031 + Placebo
QGE031 + Placebo is a phase 2 stage product being developed by Novartis for Peanut Allergy. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01451450. Target conditions include Peanut Allergy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01451450 | Phase 2 | Withdrawn |
| NCT02336425 | Phase 2 | Terminated |
| NCT01688882 | Phase 2 | Terminated |
| NCT01596712 | Phase 1 | Completed |
Competing Products
20 competing products in Peanut Allergy